The Potential Role of Dyslipidemia in COVID-19 Severity: an Umbrella Review of Systematic Reviews

키워드

참고문헌 (64)

1. Wortham JM, "Characteristics of persons who died with COVID-19-United States, February 12–May 18, 2020", MMWR Morb Mortal Wkly Rep, 69, pp.923~929 (2020)
2. Leung JM, "COVID-19 and COPD", Eur Respir J, 56, pp.2002108~ (2020)
3. Hartmann-Boyce J, "Asthma and COVID-19: review of evidence on risks and management considerations", BMJ Evid Based Med (2020)
4. Alqahtani JS, "Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19 : a rapid systematic review and meta-analysis", PLoS One, 15, pp.e0233147~ (2020)
5. Shi S, "Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China", JAMA Cardiol, 5, pp.802~810 (2020)
6. Shi Q, "Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China : a two-center, retrospective study", Diabetes Care, 43, pp.1382~1391 (2020)
7. Gao C, "Association of hypertension and antihypertensive treatment with COVID-19 mortality : a retrospective observational study", Eur Heart J, 41, pp.2058~2066 (2020)
8. Clerkin KJ, "COVID-19 and cardiovascular disease", Circulation, 141, pp.1648~1655 (2020)
9. Barron E, "Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England : a whole-population study", Lancet Diabetes Endocrinol, 8, pp.813~822 (2020)
10. Kumar A, "Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis", Diabetes Metab Syndr, 14, pp.535~545 (2020)
11. Zhang J, "Association of hypertension with the severity and fatality of SARS-CoV-2 infection : a meta-analysis", Epidemiol Infect, 148, pp.e106~ (2020)
12. Hu X, "Declined serum high density lipoprotein cholesterol is associated with the severity of COVID-19 infection", Clin Chim Acta, 510, pp.105~110 (2020)
13. Wang G, "Low high-density lipoprotein level is correlated with the severity of COVID-19 patients : an observational study", Lipids Health Dis, 19, pp.204~ (2020)
14. Aromataris E, "Summarizing systematic reviews : methodological development, conduct and reporting of an umbrella review approach", Int J Evid-Based Healthc, 13, pp.132~140 (2015)
15. Higgins JPT, "Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series" (2008), Wiley-Blackwell
16. Smith V, "Methodology in conducting a systematic review of systematic reviews of healthcare interventions", BMC Med Res Methodol, 11, pp.15~ (2011)
17. Whitlock EP, "Using existing systematic reviews in complex systematic reviews", Ann Intern Med, 148, pp.776~782 (2008)
18. Shea BJ, "AMSTAR 2 : a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both", BMJ, 358, pp.j4008~ (2017)
19. Jung JH, "Reaching for the stars-rating the quality of systematic reviews with the Assessment of Multiple Systematic Reviews(AMSTAR)2", BJU Int, 122, pp.717~718 (2018)
20. Shea BJ, "AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews", J Clin Epidemiol, 62, pp.1013~1020 (2009)
21. Guyatt G, "GRADE guidelines : 1. Introduction-GRADE evidence profiles and summary of findings tables", J Clin Epidemiol, 64, pp.383~394 (2011)
22. ElGohary GM, "The risk and prognosis of COVID-19 infection in cancer patients: a systematic review and meta-analysis", Hematol Oncol Stem Cell Ther (2020)
23. Fatima N, "Impact of COVID-19 on neurological manifestations : an overview of stroke presentation in pandemic", Neurol Sci, 41, pp.2675~2679 (2020)
24. Huang I, "Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia-A systematic review, meta-analysis, and meta-regression", Diabetes Metab Syndr, 14, pp.395~403 (2020)
25. Li J, "Meta-analysis investigating the relationship between clinical features, outcomes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia", Am J Infect Control. (2020)
26. Lippi G, "Physical inactivity and cardiovascular disease at the time of coronavirus disease 2019(COVID-19)", Eur J Prev Cardiol, 27, pp.906~908 (2020)
27. Mirzaei H, "COVID-19 among people living with HIV: a systematic review", AIDS Behav. (2020)
28. Oyelade T, "Prognosis of COVID-19 in patients with liver and kidney diseases : an early systematic review and meta-analysis", Trop Med Infect Dis, 5, pp.80~ (2020)
29. Piepoli MF, "Editor's presentation : staying healthy and fighting cardiovascular disease at the time of COVID", Eur J Prev Cardiol, 27, pp.899~902 (2020)
30. Pranata R, "Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression", J Stroke Cerebrovasc Dis, 29, pp.104949~ (2020)
31. Pranata R, "Elevated N-terminal pro-brain natriuretic peptide is associated with increased mortality in patients with COVID-19 : systematic review and meta-analysis", Postgrad Med J, 96, pp.387~391 (2020)
32. Russo V, "Covid-19 and heart : from clinical features to pharmacological implications", J Clin Med, 9, pp.1944~ (2020)
33. Vidali S, "D-dimer as an indicator of prognosis in SARS-CoV-2 infection : a systematic review", ERJ Open Res, 6, pp.00260~2020 (2020)
34. Wynants L, "Prediction models for diagnosis and prognosis of covid-19 infection : systematic review and critical appraisal", BMJ, 369, pp.m1328~ (2020)
35. Zheng Z, "Risk factors of critical & mortal COVID-19 cases : a systematic literature review and meta-analysis", J Infect, 81, pp.e16~e25 (2020)
36. Moriarty PM, "Lipoprotein(a)and its potential association with thrombosis and inflammation in COVID-19 : a testable hypothesis", Curr Atheroscler Rep, 22, pp.48~ (2020)
37. Tamara A, "Obesity as a predictor for a poor prognosis of COVID-19 : a systematic review", Diabetes Metab Syndr, 14, pp.655~659 (2020)
38. Hariyanto TI, "Dyslipidemia is associated with severe coronavirus disease 2019(COVID-19)infection", Diabetes Metab Syndr, 14, pp.1463~1465 (2020)
39. Zaki N, "Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality : a systematic review", Diabetes Metab Syndr, 14, pp.1133~1142 (2020)
40. Hu X, "Low serum cholesterol level among patients with COVID-19 infection in Wenzhou, China (February 21, 2020)", Lancet (2020)
41. Nie S, "Metabolic disturbances and inflammatory dysfunction predict severity of coronavirus disease 2019 (COVID-19): a retrospective study", medRxiv, ~ (2020)
42. Peng Y, "Cholesterol metabolism--Impacts on SARS-CoV-2 infection prognosis", medRxiv, ~ (2020)
43. Meher G, "Membrane cholesterol modulates oligomeric status and peptide-membrane interaction of severe acute respiratory syndrome coronavirus fusion peptide", J Phys Chem B, 123, pp.10654~10662 (2019)
44. Ren X, "Importance of cholesterol for infection of cells by transmissible gastroenteritis virus", Virus Res, 137, pp.220~224 (2008)
45. Petrilli CM, "Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City : prospective cohort study", BMJ, 369, pp.m1966~ (2020)
46. Li Y, "Changes in lipid metabolism in patients with severe COVID-19", Research Square (2020)
47. Chang MC, "Risk factors for disease progression in COVID-19 patients", BMC Infect Dis, 20, pp.445~ (2020)
48. Chen Q, "Clinical characteristics of 145 patients with corona virus disease 2019(COVID-19)in Taizhou, Zhejiang, China", Infection, 48, pp.543~551 (2020)
49. Simonnet A, "High prevalence of obesity in severe acute respiratory syndrome coronavirus-2(SARS-CoV-2)requiring invasive mechanical ventilation", Obesity(Silver Spring), 28, pp.1195~1199 (2020)
50. To KK, "Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2 : an observational cohort study", Lancet Infect Dis, 20, pp.565~574 (2020)
51. Zhang C, "A Novel scoring system for prediction of disease severity in COVID-19", Front Cell Infect Microbiol, 10, pp.318~ (2020)
52. Zhang JJ, "Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China", Allergy, 75, pp.1730~1741 (2020)
53. Soy M, "Cytokine storm in COVID-19 : pathogenesis and overview of anti-inflammatory agents used in treatment", Clin Rheumatol, 39, pp.2085~2094 (2020)
54. Tall AR, "Cholesterol, inflammation and innate immunity", Nat Rev Immunol, 15, pp.104~116 (2015)
55. McKechnie JL, "The innate immune system : fighting on the front lines or fanning the flames of COVID-19?", Cell Host Microbe, 27, pp.863~869 (2020)
56. Kim JA, "Role of lipotoxicity in endothelial dysfunction", Heart Fail Clin, 8, pp.589~607 (2012)
57. Fan J, "Letter to the Editor : Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019", Metabolism, 107, pp.154243~ (2020)
58. Wei X, "Hypolipidemia is associated with the severity of COVID-19", J Clin Lipidol, 14, pp.297~304 (2020)
59. Cao X, "Cholesterol : a new game player accelerating vasculopathy caused by SARS-CoV-2?", Am J Physiol Endocrinol Metab, 319, pp.E197~E202 (2020)
60. Zhang XJ, "In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19", Cell Metab, 32, pp.176~187 (2020)
61. Eckard AR, "The role of statins in the setting of HIV infection", Curr HIV, 2015, pp.12, 305~312
62. Castiglione V, "Statin therapy in COVID-19 infection", Eur Heart J Cardiovasc Pharmacother, 6, pp.258~259 (2020)
63. Nie X, "Multi-organ proteomic landscape of COVID-19 autopsies", medRxiv, ~ (2020)
64. Abu-Farha M, "The role of lipid metabolism in COVID-19 virus infection and as a drug target", Int J Mol Sci, 21, pp.3544~ (2020)

관련 논문AI추천